Spain - Diagnostic Tests for Early-Cancer-Detection

Leading molecular-diagnostics-company focused on early cancer detection (colon, lung, and pancreas) tests which are based on non-invasive-assays tested in blood, avoiding complications and side effects of existing procedures and improving the accuracy and compliance of currently marketed tests. The most advanced product: a test for colorectal cancer diagnosis through a gene signature of micro-RNA. The clinical validation of the test is currently undergoing a European prospective study and is planned to obtain CE-Mark in the coming months to be commercialized in 2019. In addition, the company is developing an ELISA-three-protein based test to be used for diagnosis of lung cancer patients and as a tool for high risk screening population. It is also developing an innovative non-invasive blood-based test for the detection of pancreatic ductal adenocarcinoma that has been validated in 164 plasma samples and a prospective clinical trial with 225 patient samples are currently being recruited from 16 hospitals.